NEUROIMAGING AND NEURODEVELOPMENTAL OUTCOME: A SECONDARY TO SURFACTANT POSITIVE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 网络--产前同意支持 三、学习目标(S)： 1)在参加支持的极早产儿中获得一致的执行、定时和解释的神经成像研究： A.出生4-14日龄的美国颅骨 B.胎龄35-42周的经颅超声 C.孕周35-42周的MRI检查 2)比较各随机通气层内低SpO2组与高SpO2组及各随机氧合层内早期CPAP组与对照通气组的早期和晚期超声及MRI表现。 3)利用NICHD新生儿研究网络后续计划评估18-22个月校正年龄的神经发育结果，如支持中所述。 4)通过预测模型检验神经影像表现与神经发育结果之间的独立联系。 A.回归模型将评估早期和晚期颅脑超声和脑MRI的绝对值和相对值，单独和结合传统危险因素，预测18-22个月时异常和正常的神经发育结果。 B.通过逐步回归建模，评估 单独和联合使用神经成像结果，可以预测神经发育结果，而不是早期风险因素或早期和住院风险因素的价值。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Network - Antenatal Consent SUPPORT I C. Study Aim(s): 1) To obtain consistently performed, timed and interpreted neuroimaging studies in extremely preterm infants enrolled in SUPPORT: a. cranial US at 4-14 days of age b. cranial US at 35-42 weeks PMA c. MRI at 35-42 weeks PMA 2) To compare early and late US and MRI findings between Low and High SpO2 groups within each randomized ventilation strata, and between Early CPAP and Control ventilation groups within each randomized oxygenation strata. 3) To utilize the NICHD Neonatal Research Network follow-up programs to assess neurodevelopmental outcomes at 18-22 months corrected age, as described in SUPPORT. 4) To examine the independent associations of neuroimaging findings with neurodevelopmental outcomes through predictive modeling. a. Regression models will assess the absolute and relative value of early and late cranial US, and brain MRI, alone and in combination with traditional risk factors, to predict abnormal and normal neurodevelopmental outcome at 18-22 months. b. Through stepwise regression modeling, assess the value of neuroimaging findings, alone and in combination, in predicting neurodevelopmental outcomes over and above the value of early risk factors or early and in-hospital risk factors alone.